Rigel reports 2024 net income $17.5M, record product sales $144.9M, guides FY25 rev $200-210M

RIGEL PHARMACEUTICALS INC

4Q total revenue $57.6M; TAVALISSE $31.0M (+21% YoY), REZLIDHIA $7.4M (+92% YoY), GAVRETO $8.1M.
FY24 total revenue $179.3M; net product sales $144.9M (+39% YoY); net income $17.5M vs loss $25.1M in FY23.
Cash & short-term investments $77.3M at year-end, up from $56.9M; expects positive net income in FY25.
FY25 guidance: total revenue $200-210M; net product sales $185-192M; contract revenues $15-18M.
R289 granted Fast Track and Orphan Drug designations for MDS; partner TAVALISSE approvals in South Korea and Mexico.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.